PYR-GLN-PHE-N-ME-PHE-SAR-LEU-MET-NH2
PYR-GLN-PHE-N-ME-PHE-SAR-LEU-MET-NH2 Basic information
- Product Name:
- PYR-GLN-PHE-N-ME-PHE-SAR-LEU-MET-NH2
- Synonyms:
-
- PYR-GLN-PHE-N-ME-PHE-SAR-LEU-MET-NH2
- GLP-GLN-PHE-(NME)PHE-SAR-LEU-MET-NH2
- [GLP5,(ME)PHE8,SAR9] SUBSTANCE P (5-11)
- (PYR5,N-ME-PHE8,SAR9)-SUBSTANCE P (5-11)
- SUBSTANCE P [PGLU5, N-ME-PHE8, SAR9]-FRAGMENT 5-11
- PGLU-GLN-PHE-N-METHYL-PHE-SAR-LEU-MET-NH2
- PGLU5,MEPHE8,SAR9-SUBSTANCE P FRAGMENT*5 -11
- SUBSTANCE P (PGLU5,MEPHE8,SAR9)-*FRAGMEN T 5-11
- CAS:
- 77128-69-9
- MF:
- C43H61N9O9S
- MW:
- 880.06
- Mol File:
- 77128-69-9.mol
PYR-GLN-PHE-N-ME-PHE-SAR-LEU-MET-NH2 Chemical Properties
- Boiling point:
- 1291.2±65.0 °C(Predicted)
- Density
- 1.257±0.06 g/cm3(Predicted)
- storage temp.
- −20°C
- form
- Solid
- pka
- 13.13±0.20(Predicted)
- color
- White to off-white
- Sequence
- pGlu-Gln-Phe-N-Methyl-Phe-Sar-Leu-Met-NH2
MSDS
- Language:English Provider:SigmaAldrich
PYR-GLN-PHE-N-ME-PHE-SAR-LEU-MET-NH2 Usage And Synthesis
Uses
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats[1][2][3].
in vivo
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (2 μg/side; inject into the ventral tegmental area; single) exhibits selective activation of mesolimbic and mesocortical dopamine metabolism in rat brain[1].
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (0.5, 1.5, 3 μg/side; inject into the ventral tegmental area; single) increases motor activity and induces recovery of addictive agent-seeking behavior in rats[2].
| Animal Model: | Male Sprague-Dawley rats (300-350 g)[1]. |
| Dosage: | 2 μg/side |
| Administration: | Inject into the ventral tegmental area; single |
| Result: | Selectively activated mesolimbic and mesocortical dopamine metabolism. |
| Animal Model: | Male Wistar rats (300-350 g)[2]. |
| Dosage: | 0.5, 1.5, 3 μg/side |
| Administration: | Inject into the ventral tegmental area; single |
| Result: | Significantly increased locomotor activity when at 3 μg/side. |
References
[1] Elliott PJ, et al. Selective activation of mesolimbic and mesocortical dopamine metabolism in rat brain by infusion of a stable substance P analogue into the ventral tegmental area. Brain Res. 1986 Jan 15;363(1):145-7. DOI:10.1016/0006-8993(86)90667-0
[2] Eison AS, et al. Substance P analog, DiMe-C7: evidence for stability in rat brain and prolonged central actions. Science. 1982 Jan 8;215(4529):188-90. DOI:10.1126/science.6171884
[3] Placenza FM, et al. Infusion of the substance P analogue, DiMe-C7, into the ventral tegmental area induces reinstatement of cocaine-seeking behaviour in rats. Psychopharmacology (Berl). 2004 Dec;177(1-2):111-20. DOI:10.1007/s00213-004-1912-9
PYR-GLN-PHE-N-ME-PHE-SAR-LEU-MET-NH2Supplier
- Tel
- 21-61263452 13641803416
- ymbetter@glbiochem.com
- Tel
- 021-54306202 13764082696
- info@hanhongsci.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 0551-65326643 18156095617
- info@cellmano.com
- Tel
- 021-QQ：65489617 15618227136
- Sales@ATKchemical.com